TSLPR

罗马 2024年4月4日 /美通社/ -- 药物研发领域的领导者 IRBM 于今日宣布，将在即将举行的美国癌症研究协会 (AACR) 年会上披露两项最具前景的内部资产的新数据，该会议将于 4 月 5 日至 10 日在圣地亚哥举行。这些数据将揭示出针对癌症治疗中尚未满足的关键需求而开发的新化合物的见解。 资产亮点： •  针对 "Ph-样" B-ALL (AM E3-SG3249) 的靶向 CRLF2/TLSPR 潜在同类首创抗体药物偶联物 (ADC)，已在临床前研究中显示出显著疗效，代表了一种开创性的治疗方法，用于治疗预后差、复发率高且常见于青少年的血液系统癌症。 •  其有望成为同类最佳的脑渗透性 SHP2 变构抑制剂 (I-1000233)，并已在临床前研究中显示出良好疗效，为治疗 RAS 所引发的恶性肿瘤（包括难治性脑肿瘤和转移）的患者提供了一种全新方法。 IRBM 首席科学官、医学博士 Carlo Toniatti 对即将举行的演讲满怀热情："AACR 大会为 IRBM 提供了一个独特的机会，让我们能够与全球科学界分享我们在癌症研究中的最新进展。我们对 CRLF2/TLSPR 的靶向 ADC 和具有 CNS 通透性的 SHP2 小分子抑制剂的研究，凸显了我们对寻找能够对癌症患者生活产生重大影响的新型治疗策略的不懈追求。这些发展反映了我们深厚的科学专业知识和创新精神，彰显了 IRBM 作为综合药物研发行业领跑者的作用。" 这两项资产已在国家化合物采集及筛选中心 (National Collection of Chemical Compounds and Screening Center，CNCCS) 的公共-私有环境中进入了探索阶段。这证明了 IRBM 的综合研究能力，及其致力于推动科学进步以改善生活，追求新的、更好的癌症治疗方法的承诺。 下方列出了海报展示的详细信息。 具有 CNS 通透性的 SHP2 抑制剂： 讲座类别： 实验和分子疗法 讲座标题： 激酶和磷酸酶抑制剂 2 讲座日期和时间： 2024 年 4 月 8 日星期一，上午 9:00 -下午 12:30 地点： 海报第 25 部分 海报板编号： 24 已发表的摘要编号： 1975 主讲者： Francesca Puca 博士、首席研究科学家 CRLF2/TLSPR 靶向 ADC ： 讲座类别： 免疫学 讲座标题： 抗体药物偶联物 讲座日期和时间： 2024 年 4 月 8 日星期一，下午 1:30-下午 5:00 地点： 海报第 2 部分 海报板编号： 13 已发表的摘要编号： 2610 主讲者： Claudia Dall 'Armi 博士、高级研究员 关于 IRBM 作为一家身处药物研发前沿的科学合同研究组织 (CRO)，IRBM 擅长利用单一、统一的研究设施，加速团队的研究进展，从而提高从概念到候选药物的转化效率。 IRBM 曾为四种已批准的药物做出过贡献，拥有自己的肿瘤学和其他治疗资产的内部管道，由全球领先机构的深度合作和数十年的专业知识提供支持。其全面的内部能力可帮助合作伙伴达成重要里程碑，并在临床就绪方面取得进展，使 IRBM 成为推动制药和生物技术领域创新的主要参与者。 关于 CNCCS 国家化合物采集及筛选中心 (CNCCS) 是由 IRBM 与意大利国家研究委员会 (CNR) 和意大利国家卫生研究院 (ISS) 于 2010 年合作创建的公私联盟。除了作为罕见、被忽视和与贫困相关的疾病领域的转化研究中心外，它还充当 "牵头工厂"的角色，识别作用于创新生物靶标的化合物。 网站： https:\/\/www.irbm.com\/ 徽标： https:\/\/mma.prnasia.com\/media2\/2354912\/IRBM_Logo.jpg?p=medium600

WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer. Mr. Kalowski brings over 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations. "Lee has been part of the Q32 Bio team over the past five months as our interim Chief Financial Officer and an invaluable member of the team driving the execution and closing of our recent transactions. I am pleased to welcome Lee as a permanent member of the team, as we transition into a publicly traded company," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "Lee is a deeply experienced biopharmaceutical executive with a proven track record of taking companies public, raising capital, and overseeing finance and operations at multiple publicly traded companies." "I am excited to be joining full-time in my new role during this transformative time for the Company," said Mr. Kalowski. "Q32 Bio has the potential to make meaningful strides in the treatment of autoimmune and inflammatory diseases and I look forward to continuing to work with the Q32 Bio leadership team as we advance bempikibart to Phase 2 clinical data in the second half of this year and ADX-097 to Phase 2 clinical data in the second half of 2025." Prior to joining Q32 Bio, Mr. Kalowski served as President and Chief Financial Officer of Bicycle Therapeutics where he led strategic finance and operations and oversaw the company's transition to a public clinical-stage biotech company. While at Bicycle, Mr. Kalowski led the IPO in 2019 and helped raise $1 Billion in total, including over $700 Million in private, public and non-dilutive financings. Prior to Bicycle, Mr. Kalowski was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company's IPO in 2014. Earlier, Mr. Kalowski served in global biotechnology equity research as a Senior Analyst at Credit Suisse covering companies in the biopharmaceutical industry. Mr. Kalowski received a B.A. in Biology and Economics from Union College and an MBA from The Wharton School of the University of Pennsylvania. Mr. Kalowski is currently a board member of Aro Biotherapeutics. About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers. For more information, visit . Forward-Looking Statements This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including bempikibart and ADX-097, and anticipated milestones and timing, among others. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to integrate our business with our merger partner successfully and to achieve anticipated synergies; the possibility that other anticipated benefits of the merger will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of our operations, and the anticipated tax treatment of the merger; our ability to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger; potential business uncertainty, including changes to existing business relationships that could affect our financial performance; the need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; the inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of global pandemics and general economic conditions on our business and operations, including the our preclinical studies and clinical trials; the possibility of system failures or security breaches; risks relating to intellectual property; significant costs incurred as a result of operating as a public company; and such other factors as are set forth in Q32 Bio's periodic public filings with the SEC, including but not limited to those described under the heading "Risk Factors" in our Form 8-filed on March 27, 2024. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Investors: Brendan Burns Media: Sarah Sutton Argot Partners 212.600.1902 [email protected] SOURCE Q32 Bio

Mike Gray appointed as CFO and COO, Lisa Fiering joins as SVP, People & Culture WALTHAM, Mass.--(BUSINESS WIRE)-- Upstream Bio, a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer. Upstream has also appointed Mike Gray as Chief Financial Officer and Chief Operating Officer, and Lisa Fiering as Senior Vice President of People & Culture. These leadership changes will support the growth and evolution of Upstream as the company works to advance verekitug, a recombinant fully human immunoglobulin G1 monoclonal antibody which blocks the thymic stromal lymphopoietin receptor (TLSPR), in ongoing Phase 2 clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). “I am thrilled to join Upstream Bio as CEO. I am committed to the company’s work to conquer inflammation at its source and intend to bring our team into the next stage of business and clinical operations,” said Dr. Sutherland. “Having dedicated much of my career to improving care for people living with asthma, I understand the substantial impact of severe respiratory diseases and I believe that verekitug could further improve standard of care for these patients. I am honored to lead this company at such an exciting time.” “Upstream Bio is at a critical period as the company advances verekitug, a potentially best-in-class therapeutic in the field of TSLP biology,” said Ron Renaud, Chair of the Board of Directors for Upstream Bio. “I want to thank Samantha Truex for serving as Upstream Bio’s CEO from launch through the initiation of our Phase 2 studies and leading the company to this juncture. By evolving and building our leadership team with these additions, we are further positioning Upstream Bio to become a leader in the immunotherapy landscape. I am pleased to welcome Rand, Mike and Lisa to the Upstream Bio team.” Dr. Sutherland joins Upstream Bio with more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics, and before that as President of Translate Bio prior to its acquisition by Sanofi. Previously, Dr. Sutherland held a number of R&D and medical affairs roles at Sanofi, providing leadership for the development of novel medicines in Immunology and Rare Diseases, and leading medical affairs globally for the Specialty Care business unit. Dr. Sutherland also serves as an independent director of Allakos, Krystal Biotech and Vanqua Bio. Before joining the biopharma industry, Dr. Sutherland was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver. He earned an MD from the University of Chicago, after which he trained in Internal Medicine at UCSF and in Pulmonary and Critical Care Medicine at the University of Colorado. Mr. Gray has more than 25 years of public-private leadership experience and was most recently the CFO and COO of Carmot Therapeutics, where he helped to secure the company’s acquisition by Roche in 2024. Before this, he was CFO and COO of Imara and Arsanis, working with the leadership teams of each company in completing initial public offerings and building leading organizations. Mr. Gray previously held a number of leadership positions at Curis. Mr. Gray served on the Board of Directors of Therapeutics Acquisition Corporation, a special purpose acquisition corporation, through its merger with POINT Biopharma, which was subsequently acquired by Eli Lilly and Company in March 2024. He received his BS in business administration (accounting) from Bryant College and an MBA in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College. Ms. Fiering brings to Upstream 30 years of experience, having spent the past 20 years in various people and culture roles at life sciences companies including Genzyme, Ironwood Pharmaceuticals, Keryx and Trillium, where she developed a pragmatic approach to drive team effectiveness through talent and organizational development. Since 2022, she has provided strategic consulting to early-stage biotech companies, developing strategy and building the foundation for the people and culture function for these growing companies. Ms. Fiering earned her BA in Sociology from Ithaca College. About Upstream Bio Upstream Bio strives to reach the source of inflammation and conquer it, leveraging its team’s diverse industry experience to develop verekitug (UPB-101) to ease the burden of respiratory diseases. Verekitug is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. Upstream has completed a clinical trial in asthma with 32 weeks of observation which demonstrated compelling and sustained reductions in disease-related biomarkers and enabled the investigation of UPB-101 in ongoing Phase 2 trials of asthma and of CRSwNP that include extended dosing regimens of up to every 24 weeks. View source version on businesswire.com: Contacts Source: Upstream Bio View this news release online at: